MeSci
Senior Member (Voting Rights)
Source: Clinical Therapeutics
Preprint
Date: May 1, 2019
URL:
https://www.sciencedirect.com/science/article/abs/pii/S0149291819301638
Searching for serum antibodies to neuronal proteins in patients with Myalgic Encephalopathy/Chronic Fatigue Syndrome
----------------------------------------------------------
Maria Pia Giannoccaro(1), Judith Cossins(1), Kari Sorland(2), Oystein Fluge(2), Angela Vincent(1)
1 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
2 Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
* Corresposponding author. Pia Giannoccaro, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK. Email: mpgiannoccaro@gmail.com
Received 12 March 2019
Revised 28 March 2019
Accepted 1 April 2019
Available online 1 May 2019.
Abstract
Purpose
A role for the immune system in causing myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is long suspected, but few studies have looked for specific autoantibodies that might contribute to the symptoms. Our aim was to look for evidence of antibodies to neuronal proteins in patients with ME/CSF.
Methods
Sera samples from 50 patients and 50 healthy individuals were sent coded to the Neuroimmunology Laboratory in Oxford. Screening for antibody binding to neuronal tissue was performed on brain tissue and neuronal cultures. Specific serum antibodies were assessed by antigen-specific cell-based assays and radioimmunoassays. After antibody testing, the associations between seropositive status and clinical data were investigated.
Findings
Overall, 8 patients and 11 participants were found to have some serum immunoreactivity toward neuronal or neuromuscular junction proteins, but only 1 patient and 2 participants had specific serum antibodies.
Nevertheless, seropositive status in patients with ME was associated with shorter duration since onset and a more severe disease.
Implications
The results indicate no overall increased frequency of antibodies to neuronal proteins in ME/CSF and no evidence of a specific antibody that might be causative or contribute to clinical features in patients.
However, the association of seropositive status with shorter duration of disease and more severe symptoms suggests a possible role of antibodies at onset in some patients and should be the focus of future studies.
Key words: antibodies; chronic fatigue syndrome; LRP4; myalgic encephalopathy; neuronal surface antigens; NMDA receptor
Preprint
Date: May 1, 2019
URL:
https://www.sciencedirect.com/science/article/abs/pii/S0149291819301638
Searching for serum antibodies to neuronal proteins in patients with Myalgic Encephalopathy/Chronic Fatigue Syndrome
----------------------------------------------------------
Maria Pia Giannoccaro(1), Judith Cossins(1), Kari Sorland(2), Oystein Fluge(2), Angela Vincent(1)
1 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
2 Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
* Corresposponding author. Pia Giannoccaro, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK. Email: mpgiannoccaro@gmail.com
Received 12 March 2019
Revised 28 March 2019
Accepted 1 April 2019
Available online 1 May 2019.
Abstract
Purpose
A role for the immune system in causing myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is long suspected, but few studies have looked for specific autoantibodies that might contribute to the symptoms. Our aim was to look for evidence of antibodies to neuronal proteins in patients with ME/CSF.
Methods
Sera samples from 50 patients and 50 healthy individuals were sent coded to the Neuroimmunology Laboratory in Oxford. Screening for antibody binding to neuronal tissue was performed on brain tissue and neuronal cultures. Specific serum antibodies were assessed by antigen-specific cell-based assays and radioimmunoassays. After antibody testing, the associations between seropositive status and clinical data were investigated.
Findings
Overall, 8 patients and 11 participants were found to have some serum immunoreactivity toward neuronal or neuromuscular junction proteins, but only 1 patient and 2 participants had specific serum antibodies.
Nevertheless, seropositive status in patients with ME was associated with shorter duration since onset and a more severe disease.
Implications
The results indicate no overall increased frequency of antibodies to neuronal proteins in ME/CSF and no evidence of a specific antibody that might be causative or contribute to clinical features in patients.
However, the association of seropositive status with shorter duration of disease and more severe symptoms suggests a possible role of antibodies at onset in some patients and should be the focus of future studies.
Key words: antibodies; chronic fatigue syndrome; LRP4; myalgic encephalopathy; neuronal surface antigens; NMDA receptor